- Home
- News
- netherlands
- insulin type
Insulin Type Articles & Analysis
17 news found
Alertgy has nearly completed the process of miniaturizing its first generation NICGM® (Non-Invasive Continuous Glucose Monitor) into a smaller form factor that will be the size of modern smart watches. By replacing commercial off-the-shelf components with custom built parts, Alertgy has been able to greatly reduce the size of its NICGM. Throughout the design process, Alertgy has aimed to ...
ByAlertgy
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
REVITA-T2Di is an open-label cohort evaluating Revita DMR® in patients with insulin-treated type 2 diabetes – Revita® in the T2Di cohort has been observed to be well tolerated and all patients previously on long-acting insulin have discontinued insulin therapy in the initial follow-up period – Regular updates on the extended follow-up of the REVITA-T2Di cohort in ...
REVITA-T2Di study is assessing potential of outpatient Revita DMR treatment to improve glycemic control and reduce or eliminate need for daily insulin – LEXINGTON, Mass., September 1, 2021 – Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the activation of the tenth ...
Toronto, Canada, July 27, 2021 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first patients in its Phase 1b trial of ZT-01. “We are excited to advance ZT-01 to the next stage of development after our recent successful ...
Toronto, Canada, May 26, 2021 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has successfully completed a Phase 1 study evaluating single and multiple ascending doses of ZT-01. “We are ...
Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the enrollment of the first patient in a pivotal clinical trial of Revita® DMR for patients with type 2 diabetes. The trial, called REVITA-T2Di, will evaluate the ability of a single Revita DMR treatment to ...
LEXINGTON, Mass., February 1, 2021 — Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today announced the publication of clinical results from the investigator-initiated INSPIRE clinical trial conducted in collaboration with Fractyl. The results demonstrate that a majority of patients ...
Toronto, Canada, September 29, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01. “Initiation of our Phase 1 study of ZT-01, which has been our goal since establishing the ...
Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01. “Initiation of our Phase 1 study of ZT-01, which has been our goal since establishing the Company in 2014, is a monumental milestone for ...
Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, presented new findings today at the 55th Annual Meeting of the European Association for the Study of Diabetes on September 16-20, 2019 in Barcelona. The company recently undertook research to determine ...
Revita® DMR is the first and only procedural therapy for type 2 diabetes; Revita DMR has been shown to durably improve blood sugar control without the need for escalating drug therapy and to reduce liver fat in NAFLD/NASH in clinical studies to date. LEXINGTON, Mass., August 6, 2020 – Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic ...
Revita T2Di pivotal study to evaluate the ability of Revita DMR, the first non-drug, non-surgical, disease-modifying therapy, to eliminate need for insulin injections in T2D; enrollment expected to begin in late 2020 LEXINGTON, Mass., June 3, 2020 — Fractyl Laboratories Inc. (Fractyl) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) of ...
Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”). The proceeds from the financing will fund Phase 1 and Phase 2 clinical trials of ...
Toronto, Canada, March 31, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”). The proceeds from the financing will fund ...
Nearly 30,000 people across the country with Type 1 diabetes have received life-changing diabetes monitors through the NHS Long Term Plan. The innovative device, which is the size of a £2 coin and worn on the arm, means people with Type 1 do not have to carry out multiple painful finger-prick checks to monitor their blood sugar levels. Instead, people with the condition can monitor their ...
Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent diabetes, has secured a grant of $69,000 from Canadian Glycomics Network (GlycoNet) to expand and validate the model for its lead drug candidate “ZT-01” from type 1 diabetes (T1D) to type 2 diabetes ...